Timeline.
Features.
"All patients must have access to rapid, personalized and affordable treatments."
NETRI, since 2018, has put this vison at the heart of its products and its story. Discover the steps NETRI has taken to develop organs-on-chip devices that finely reproduce and digitize human biology.
• Story of a fast-growing company
• All product lines chronology
• Introduced the NeuroFluidics™ MEA Line , co-developed with Axion BioSystems, along with UpLink utility software for MEA metric evaluation.
• Introduced organs-on-chip kits in three packages: Models OoC Kits, Starter OoC Kits and Training OoC Kits.
• Introduced Pain & Injury model with a specific use case about Chemotherapy Induced Peripheral Neuropathy and Innervated skin model with co-culture of hiPSC sensory neurons and primary keratinocytes.
• Introduced the NeuroFluidics™ Line with 3 organs-on-chip devices.
• Introduced NeoBento high-throughput platform compatible with laboratory equipment and pumpless & standalone platform.
• Introduced Axotomy model with DuaLink Delta Ultra.
• Introduced the NeuroBento high-throughput format.
• Validation of five human iPSC-Derived Neurons with standard operating protocol.
• Labelled Deeptech from Bpifrance.
• Introduced six new architectures of organs-on-chip devices
• Development of a high-throughput format
•
Set up in the competitiveness cluster Lyonbiopôle, in the Gerland biodistrict
• Introduced first commercial unit chips
•
NETRI is founded by Thibault Honegger, CEO, and Florian Larramendy, CTO.
• Development of first-unit chips
